Viramune Labeling Revised To Require Liver Monitoring In First 12 Weeks
Executive Summary
Revised black box labeling for Boehringer Ingelheim/Roxane antiretroviral Viramune (nevirapine) states that patients must receive liver monitoring during the first 12 weeks of therapy.
You may also be interested in...
Boehringer modifies Viramune warning
Boehringer Ingelheim will modify "black box" warning for HIV agent Viramune to highlight that women with CD4+ count >250 cells/mm receiving chronic treatment are at high risk for hepatotoxicity, company "Dear Doctor" letter says. Boehringer has previously modified the box warning to recommend that patients be monitored for hepatotoxicity during the first three to four months of therapy (1"The Pink Sheet" Nov. 13, 2000, p. 22)...
Boehringer modifies Viramune warning
Boehringer Ingelheim will modify "black box" warning for HIV agent Viramune to highlight that women with CD4+ count >250 cells/mm receiving chronic treatment are at high risk for hepatotoxicity, company "Dear Doctor" letter says. Boehringer has previously modified the box warning to recommend that patients be monitored for hepatotoxicity during the first three to four months of therapy (1"The Pink Sheet" Nov. 13, 2000, p. 22)...
Triangle Coviracil Study Completion Funded Via $100 Mil. Equity Facility
Triangle Pharmaceuticals' $100 mil. equity facility appears to be sufficient to finance the company until it completes clinical development of the HIV nucleoside analogue Coviracil (emtricitabine).